Burlington, MA, United States of America

Momar Toure

This inventor holds 1 USPTO granted patent. Top assignee: Moma Therapeutics. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Momar Toure. Retrieved from https://idiyas.com/inventor/momar-toure-m6bttqea

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Momar Toure: Inventor in Biotechnology

Introduction

Momar Toure is an inventor based in Burlington, Massachusetts, whose patent work concerns compounds that may help modulate Werner Helicase (WRN) activity. He is associated with Moma Therapeutics.

Latest Patents

Toure is named on 1 patent, titled “Tricyclic Derivatives and Related Uses.” The disclosure covers compounds of Formula (I′), along with their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of preparation. The compounds are described as useful for modulating WRN activity and may have applications in treating disorders in which WRN is implicated, including cancer.

Career Highlights

The patent reflects Toure’s involvement in research and development focused on therapeutic compounds and potential cancer treatments. His work is associated with Moma Therapeutics.

Collaborations

Toure’s listed coworker is Meredeth A. McGowan. Their shared professional context is connected to Moma Therapeutics and research involving WRN-targeting compounds.

Conclusion

Momar Toure’s patent work highlights the development of tricyclic compounds with potential applications in modulating WRN activity and treating cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…